In the mid 1990s, the genomics industry was at its peak with unprecedented growth and activity. Indeed, the objective was to sequence all the genes within the human genome. The rationale behind this ambitious project was that if we could achieve the complete catalogue of all the genes within the human genome, we could better understand the molecular basis of disease. A better understanding of disease would result in better drugs; drugs that would not only address the symptoms of a disease, but rather its root genetic cause.

GeneChem manages specialised venture capital funds that target companies in the genomics industry. GeneChem actively supports companies that discover and develop novel therapeutics from genomic targets.

GeneChem has an experienced team that is actively seeking investment opportunities in the genomics industry on an international basis.